Tricals - The highway towards a cure
Centre SLA de Paris

University Hospital Pitié-Salpêtrière

France - Paris

The Paris ALS expert center, based at the La Pitié Salpêtrière University Hospital - AP-HP, provides expert, multi-disciplinary support for ALS patients, from the moment they are diagnosed and throughout their follow-up.

The objectives of the Paris ALS Reference Center are:
– Improve access to diagnosis and provide support during the announcement phase;
– organize the interdisciplinary
– Participate in data collection and research  programs;
– Participate in the activities of the FILSLAN, source: portail-sla.fr

Headed by Dr François Salachas, the Paris ALS expert Center of the Pitié-Salpêtrière Hospital was created in 2002, and is one of the largest ALS centers in Europe in terms of both the number of new patients per year (400-500 /y) and the number of active patients (1400-1500/y), mostly patients with ALS but also with rare motor neuron disorders such as Primary Lateral Sclerosis or Kennedy’s disease). The Center’s team provides care at all stages of the disease, from diagnosing to treating complications. It offers a multidisciplinary approach and provides education for patients, families, students and health care professionals. Overall, the Center is dedicated to provide excellence in care for ALS patients while accelerating the development of effective treatments. The Paris ALS expert center’s team consists of 6 ALS expert neurologists and 1 expert in neurophysiology, all of whom are involved in both routine care activity and clinical trials involving ALS and MND patients.

For its clinical research activities, the Paris ALS expert center relies on a dedicated Clinical Research Team, coordinated by Prof Gaelle Bruneteau at the Clinical Investigation Center (CIC) of the Paris Brain Institute (Pitié-Salpêtrière Hospital).

The CIC Neurosciences has dedicated offices and staff trained in clinical research to study neurological notably the ALS, under optimum conditions of quality, ethics and safety. It also has an MRI department with 2 MRI 3T MRI.

The ALS Clinical Research Team consists of one dedicated neurologist, one full-time project manager and two FTE clinical research associates (CRAs).

Over the past five years (2017-2023 period), the team has been involved in 15 therapeutic trials in the field of ALS and MNDs.

Location

7/83 boulevard de l’Hôpital, 75651,Paris,France

Contact

Specialists in this centre

François Salachas

Neurologist

Gaelle Bruneteau

Neurologist

Current trials in this centre

Open for participation

PREVAiLS Study

Phase 3
Industry
No

The PREVAiLS Study is a clinical study that evaluates whether the study drug pridopidine, can help people living with ALS.

More about this trial

Closed for participation

DAZALS

Phase 2
Industry
No

In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS.

More about this trial

Closed for participation

ATLAS

Phase 3
Industry
SOD1

This trial evaluates the efficacy and safety and of an investigational drug for pre-symptomatic carriers of the SOD1 gene.

More about this trial

Closed for participation

reALiSe

Phase 2
Industry
No

In the reALiSe study the safety and efficacy of the drug ARGX-119 for the treatment of ALS is investigated.

More about this trial

Archived

PHOENIX

Phase 3
Industry
No

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035'.

More about this trial

Archived

ADORE

Phase 3
Industry
No

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of FNP122 for people with ALS.

More about this trial

Archived

VALOR

Phase 3
Industry
SOD1

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with ALS.

More about this trial

Archived

COURAGE-ALS

Phase 3
Industry
No

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS.

More about this trial

Archived

ALXN1210-ALS-308 trial

Phase 3
Industry
No

This study is designed to test the efficacy and safety of intravenous Ravulizumab in patients with ALS.

More about this trial

Contact this centre

If you would like to contact us or register for a trial, leave your details here.